Came across this article discussing recent advancements in circulating tumor DNA (ctDNA) technology for detecting minimal residual disease (MRD) post-surgery/treatment. Seems like sensitivity is improving, potentially offering a better way to stratify risk and guide adjuvant therapy decisions. Thought folks here, especially those using or considering Signatera/other assays, might find it interesting. Article

  • J.G.English
    1·
    8 months ago

    For those of us in the metastatic setting, ctDNA is often used to monitor treatment response and detect new mutations. Improvements in sensitivity are definitely welcome. Helps guide treatment changes faster than scans sometimes.

    • williammillerOPEnglish
      1·
      8 months ago

      Absolutely, Joseph. Its role in monitoring response and guiding later-line therapies is another crucial application. Hope your current treatment path is managing things well.